Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SpyCas9 is a Class 2 Type II CRISPR-associated endonuclease derived from *Streptococcus pyogenes* that serves as the foundational component for many programmable genome-editing technologies. It functions as an RNA-guided DNA nuclease, forming a ribonucleoprotein (RNP) complex with a single-guide RNA (sgRNA) to recognize and cleave double-stranded DNA targets. Recognition is mediated by a 20-nucleotide sequence complementary to the guide RNA and an adjacent 5'-NGG-3' protospacer adjacent motif (PAM). Upon binding, the enzyme's HNH and RuvC nuclease domains generate a double-strand break (DSB), which can be repaired by cellular mechanisms to introduce gene knockouts or precise sequence insertions. SpyCas9 is extensively utilized in clinical-stage gene therapies, such as those for sickle cell disease and transthyretin amyloidosis, and in the engineering of allogeneic cell therapies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SpyCas9.